Article

Avoiding the TRIPS Trap: A Path to Domestic Disclosure of Clinical Drug Data Consistent with International Norms

2020-08-10

Abstract excerpt

Should doctors, patients and policy makers have complete information about new drugs? Although complete transparency may seem like the obvious answer, the reality is that publicly available information is often incomplete. Before a drug may be approved for sale, a regulatory agency such as the Food and Drug Administration (FDA) will review extensive data created by a company seeking approval of such a drug. How...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 81b5fbba-8573-5117-b6a0-bbb6bd8a01c6
DOI: 10.2139/ssrn.3667995

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Avoiding the TRIPS Trap: A Path to Domestic Disclosure of Clinical Drug Data Consistent with International NormsDOI 10.2139/ssrn.3667995Read

Beyond Traditional IP: Addressing Regulatory BarriersSemantic proximity Read

Prepared Oral Statement of Professors David S. Levine and Joshua D. Sarnoff in ITC Investigation 332-996, on COVID-19 Diagnostics and Therapeutics: Supply, Demand, and Trips Agreement FlexibilitiesSemantic proximity Read

Trust and Trade: Patient Perspectives on the Ethics of Real-World Data MonetisationSemantic proximity Read

Trust and Trade: Patient Perspectives on the Ethics of Real-World Data MonetisationSemantic proximity Read

COVID-19 Trade Secrets and Information Access: An OverviewSemantic proximity Read

Compelling Trade Secret TransfersSemantic proximity Read

The Role of Intellectual Property Rights on Access to Medicines in the WHO African Region: 25 Years After the TRIPS AgreementSemantic proximity Read

Ethical and human subject burdens of trials conducted to evaluate biosimilarsSemantic proximity Read

Revisiting Canada’s Access to Medicines Regime in Response to COVID-19: A Review of the Legislation and its Underlying ObjectivesSemantic proximity Read

“A Process-Based Approach to Conflicts of Interest”Semantic proximity Read

Global Patterns in Access and Benefit-Sharing: A Comprehensive Review of National PoliciesSemantic proximity Read

Data sharing policies, requirements, and support from public and private clinical trial sponsors: a survey on top sponsors of clinical trials in EuropeSemantic proximity Read